Secukinumab sustains early patient-reported outcome benefits through 1 year: Results from 2 phase III randomized placebo-controlled clinical trials comparing secukinumab with etanercept - 18/04/17
, Lori McLeod, PhD d, Todd Fox, PharmD f, Margaret Mordin, MS e, Ari Gnanasakthy, MSc, MBA g, Charis Papavassilis, MD, PhD f, Mark G. Lebwohl, MD hAbstract |
Background |
Psoriasis is a chronic condition with negative impact on patients' quality of life that most often requires lifelong effective and safe treatment.
Objective |
This analysis focused on the effect of secukinumab treatment on patient-reported health-related quality of life as assessed by the Dermatology Life Quality Index (DLQI) in patients with moderate to severe psoriasis.
Methods |
The proportion of subjects achieving DLQI score 0/1 response at week 24, time to DLQI score 0/1 response, and sustained DLQI score 0/1 response up to week 52 were compared between secukinumab and etanercept.
Results |
Of 1470 subjects, 1144 received secukinumab and 326 received etanercept. DLQI score 0/1 response rates were significantly higher for secukinumab than for etanercept at week 24. The median time to DLQI score 0/1 response was significantly shorter for secukinumab versus etanercept (12 vs 24 weeks; P < .01). The majority of secukinumab-treated subjects achieved DLQI score 0/1 response at week 24 and sustained it through week 52 along with a 90% to 100% reduction in the Psoriasis Area and Severity Index total score response.
Limitations |
Placebo comparisons are limited during the maintenance period because of rerandomization at week 12.
Conclusion |
Secukinumab treatment provided faster and greater sustained improvements in quality of life than etanercept over 52 weeks, consistent with greater clinical response.
Le texte complet de cet article est disponible en PDF.Key words : Dermatology Life Quality Index, patient-reported outcome, psoriasis, secukinumab
Abbreviations used : DLQI, IL, PASI, QOL
Plan
| Supported by Novartis Pharmaceuticals. |
|
| Disclosure: Dr Strober has served as part of the speakers' bureau for AbbVie; as a consultant for AbbVie, Amgen, Celgene, Dermira, Janssen, LEO Pharma, Lilly, Maruho, Medac, Merck, Novartis, Pfizer, Stiefel/GlaxoSmithKline, and UCB; as an investigator for AbbVie, Amgen, Novartis, Lilly, Janssen, and Merck; and as a scientific director for Corrona Psoriasis Registry; and receives grant support through the University of Connecticut from AbbVie and Janssen. Dr Gottlieb has consulted or served on advisory boards for Amgen Inc, Astellas, Akros, Centocor (Janssen) Inc, Celgene Corp, Bristol Myers Squibb Co, Beiersdorf Inc, Abbott Labs (Abbvie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd, Incyte, Pfizer, Canfite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, Glaxo Smith Kline, Xenoport, Catabasis, Meiji Seika Pharma Co Ltd, Takeda, Mitsubishi Tanabe Pharma Development America Inc, Genentech, and Baxalta; and participated in research/educational grants for Centocor (Janssen), Amgen, Abbott (Abbvie), Novartis, Celgene, Pfizer, Lilly, Coronado, Levia, Merck, Xenoport, Dermira, and Baxalta. Ms Sherif, Dr McLeod, and Ms Mordin are full-time employees of RTI Health Solutions. Drs Fox and Papavassilis and Ms Gilloteau are full-time employees of Novartis. Dr Mollon and Mr Gnanasakthy were full-time employees of Novartis. Dr Lebwohl is an employee of the Mount Sinai Medical Center, which receives research funds from AbGenomics, AbbVie, Amgen, Anacor, Aqua, Canfite Biopharma, Celgene, Clinuvel, Coronado Biosciences, Ferndale, Lilly, Janssen Biotech, LEO Pharma, Merz, Novartis, Pfizer, Sandoz, Sun Pharmaceuticals, and Valeant. |
Vol 76 - N° 4
P. 655-661 - avril 2017 Retour au numéro
Article précédent
- Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis
- Marlena Hawro, Marcus Maurer, Karsten Weller, Romuald Maleszka, Anna Zalewska-Janowska, Andrzej Kaszuba, Zofia Gerlicz-Kowalczuk, Tomasz Hawro
- Biologic drug survival in Israeli psoriasis patients
- Guy Shalom, Arnon D. Cohen, Michael Ziv, Cohen Barak Eran, Ilan Feldhamer, Tamar Freud, Eitan Berman, Shirley Oren, Emmilia Hodak, Lev Pavlovsky
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?